ArticleChemistry & biodiversity2026
CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Carbonic anhydrase IX (CA IX) is overexpressed in many solid tumors, contributing to cancer cell proliferation, survival, invasion, and metastasis. Sulfonamide-based compounds have emerged as potential anticancer agents by inhibiting this enzyme. In this study, we investigated the anticancer potential of a previously synthesized sulfonamide derivative, MMH-I, focusing on its CA IX-targeted activity and therapeutic efficacy in both in vitro and in vivo models of breast cancer. Cytotoxicity was assessed using MTT assays in 4T1 breast cancer cells, while apoptosis was evaluated by acridine orange/ethidium bromide staining and Annexin V detection. In vivo studies analyzed tumor tissues for CA IX expression, as well as Vimentin, E-Cadherin, and Caspase-3 levels. H&E staining and plasma metabolomic analysis were performed to assess tissue morphology and metabolic alterations. The compound significantly reduced tumor volume, induced apoptosis, and altered cancer-related gene expression and metabolic profiles. Overall, this study provides a detailed in vivo and metabolic evaluation of MMH-I in breast cancer, highlighting its potential as a CA IX-targeted therapeutic candidate and supporting further investigation of sulfonamide-based combination strategies against hypoxic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.